NIRVF (Nirvana Life Sciences) Total Liabilities: $0.53 Mil (As of Jan. 2026)


What is Nirvana Life Sciences Total Liabilities?

Nirvana Life Sciences NIRVF Total Liabilities is $0.53 Mil as of Jan. 2026. The stock has 3 warning signs investors should review.

Nirvana Life Sciences's Total Liabilities for the quarter that ended in Jan. 2026 was $0.53 Mil.

Nirvana Life Sciences's quarterly Total Liabilities increased from Jul. 2025 ($0.40 Mil) to Oct. 2025 ($1.19 Mil) but then declined from Oct. 2025 ($1.19 Mil) to Jan. 2026 ($0.53 Mil).

Nirvana Life Sciences's annual Total Liabilities increased from Apr. 2023 ($0.75 Mil) to Apr. 2024 ($0.85 Mil) and increased from Apr. 2024 ($0.85 Mil) to Apr. 2025 ($1.08 Mil).

Nirvana Life Sciences Total Liabilities Historical Data

* Premium members only.

The historical data trend for Nirvana Life Sciences's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nirvana Life Sciences Total Liabilities Chart

Nirvana Life Sciences Annual Data
Trend Oct18 Oct19 Oct20 Oct21 Apr22 Apr23 Apr24 Apr25
Total Liabilities
Get a 7-Day Free Trial 0.44 0.51 0.75 0.85 1.08

Nirvana Life Sciences Quarterly Data
Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.94 1.08 0.40 1.19 0.53

Nirvana Life Sciences Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Nirvana Life Sciences's Total Liabilities for the fiscal year that ended in Apr. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=1.079+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=1.08

Total Liabilities=Total Assets (A: Apr. 2025 )-Total Equity (A: Apr. 2025 )
=0.014--1.064
=1.08

Nirvana Life Sciences's Total Liabilities for the quarter that ended in Jan. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=0.467+(0+0.063
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=0.53

Total Liabilities=Total Assets (Q: Jan. 2026 )-Total Equity (Q: Jan. 2026 )
=0.015--0.515
=0.53

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $0.53 Mil mean?
Nirvana Life Sciences (NIRVF) has a Total Liabilities of $0.53 Mil as of Jan. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Nirvana Life Sciences and its competitors.
Is Nirvana Life Sciences' Total Liabilities too high?
Nirvana Life Sciences' current Total Liabilities is $0.53 Mil.
How does Nirvana Life Sciences' Total Liabilities compare to VRTX and REGN?
Nirvana Life Sciences' Total Liabilities of $0.53 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Nirvana Life Sciences and its competitors. Nirvana Life Sciences's current Total Liabilities is $0.53 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nirvana Life Sciences stock overvalued right now?
Nirvana Life Sciences (NIRVF) has a current Total Liabilities of $0.53 Mil. The current Total Liabilities is $0.53 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Nirvana Life Sciences (NIRVF), the current Total Liabilities is $0.53 Mil as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nirvana Life Sciences Business Description

Other Exchanges NIRV.X:Canada
Address 650 West Georgia Street, Suite 2110, Vancouver, BC, CAN, V6B 4N8
Nirvana Life Sciences Inc is a Canada-based company, which is engaged in the scientific research and development of therapeutic products derived from psychedelics. The Company is also focused on developing methodologies for standardized, quality-controlled extraction and purification of psychoactive compounds. The Company operates in a single reportable segment: research and development of therapeutic products derived from psychedelics. The company is working on novel formulations of psilocybin and other naturally-sourced psychedelics to treat pain, opioid dependency, and other health problems.